FDA OKs Application for Immunic’s UC Therapy, Green-lighting Phase 2 Trial

FDA OKs Application for Immunic’s UC Therapy, Green-lighting Phase 2 Trial
The U.S. Food and Drug Administration has cleared the way for Immunic Therapeutics to begin a Phase 2 trial testing IMU-838, its therapy candidate for ulcerative colitis. The FDA's approval of Immunic's investigational new drug (IND) application allows the biotech company to initiate the clinical trial (NCT03341962), which will evaluate the safety and effectiveness of different doses of IMU-838 in 150 adults in the U.S. and Europe with moderate to severe ulcerative colitis (UC). A second Phase 2 trial is planned by Immunic in Crohn's disease patients after interim results are collected from the UC study. IMU-838 is a selective immune system modulator. It is designed to target the intracellular metabolism of immune cells by blocking an enzyme called dihydroorotate dehydrogenase (DHODH). In this way, the drug inhibits key T-cells as well as activated B-cells that may drive inflammation, without increasing the risk of viral infections. In two past Phase 1 trials, IMU-838 was shown to have good safety and pharmacokinetics (how a drug is processed in the body) properties. The Phase 2 trial, called CALDOSE-1, is the first part of company's global development plan designed to demonstrate clinical efficacy of IMU-838 for inflammatory bowel disease (IBD). Immunic's drug development programs include small molecule inhibitors for the treatment of UC, Cro
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *